Skip to main content

Industry doubts pausing the EU reg machine will offer relief

Market participants are sceptical that a proposal to halt certain rulemaking will reduce compliance costs or boost growth

Pharmaceutical industry production line

After years of churning out regulation, the European Union has been reflecting on the impact of its prolific rulemaking. Now – in a bid to slow its conveyor belt of rules – it is contemplating postponing a slew of secondary regulation.

At the same time, rising geopolitical tensions have highlighted the need for a thriving economy in Europe, and mounting compliance costs from an ever-growing slate

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Want to know what’s included in our free membership? Click here

Show password
Hide password

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here